ABIOMED, Inc. (NASDAQ:ABMD) – Equities research analysts at Jefferies Group increased their Q4 2018 earnings estimates for shares of ABIOMED in a report released on Thursday, Zacks Investment Research reports. Jefferies Group analyst R. Denhoy now forecasts that the medical equipment provider will post earnings of $0.62 per share for the quarter, up from their prior estimate of $0.50. Jefferies Group currently has a “Buy” rating and a $300.00 target price on the stock.
Other research analysts have also issued reports about the stock. Guggenheim reaffirmed a “buy” rating and issued a $280.00 price objective on shares of ABIOMED in a research note on Friday, February 2nd. Piper Jaffray Companies reissued a “positive” rating and set a $300.00 price target (up from $220.00) on shares of ABIOMED in a research report on Thursday, February 1st. Leerink Swann raised their price target on shares of ABIOMED to $300.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. BTIG Research reissued a “hold” rating on shares of ABIOMED in a research report on Sunday, October 29th. Finally, Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price target on the stock in a research report on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $263.86.
ABIOMED (NASDAQ ABMD) traded up $0.27 during trading on Monday, hitting $233.99. 313,800 shares of the company’s stock were exchanged, compared to its average volume of 394,636. ABIOMED has a 12-month low of $108.21 and a 12-month high of $255.42. The company has a market capitalization of $11,070.00, a price-to-earnings ratio of 126.43, a price-to-earnings-growth ratio of 3.10 and a beta of 0.36.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.20. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The firm had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. During the same period last year, the firm earned $0.34 earnings per share. The business’s quarterly revenue was up 34.9% compared to the same quarter last year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Crow Point Partners LLC bought a new position in shares of ABIOMED in the fourth quarter valued at approximately $120,000. Cerebellum GP LLC bought a new position in shares of ABIOMED in the fourth quarter valued at approximately $127,000. SeaCrest Wealth Management LLC bought a new position in shares of ABIOMED in the fourth quarter valued at approximately $183,000. Rehmann Capital Advisory Group bought a new position in shares of ABIOMED in the third quarter valued at approximately $202,000. Finally, Sigma Planning Corp bought a new position in shares of ABIOMED in the third quarter valued at approximately $206,000. Hedge funds and other institutional investors own 90.35% of the company’s stock.
WARNING: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/q4-2018-earnings-forecast-for-abiomed-inc-abmd-issued-by-jefferies-group.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Get a free copy of the Zacks research report on ABIOMED (ABMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.